ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

June 14, 2024

https://www.globenewswire.com/news-release/2024/06/14/2899196/0/en/ASLAN-Pharmaceuticals-Announces-Plan-to-Implement-ADS-Ratio-Change.html

SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.